OverviewSuggest Edit

Synergy Pharmaceuticals is a biopharmaceutical company focusing on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its only commercial product is plecanatide (brand name Trulance) which is used for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide, a product candidate to treat mild-to-moderate ulcerative colitis.

StateClosed
TypePublic
Founded1992
HQNew York, US
Websitesynergypharma.com
Employee Ratings2.7

Latest Updates

Employees (est.) (Dec 2017)116(-62%)
Revenue (FY, 2017)$16.8 M
Share Price (Mar 2019)$0 (-51%)

Key People/Management at Synergy Pharmaceuticals

Pharm.D Troy Hamilton

Pharm.D Troy Hamilton

Director and Chief Executive Officer
Patrick Griffin

Patrick Griffin

Executive Vice President and Chief Medical Officer
Gary G. Gemignani

Gary G. Gemignani

Executive Vice President and Chief Financial Officer
Marianne Jackson

Marianne Jackson

Senior Vice President, Sales & Market Access
Dan Dunham

Dan Dunham

Senior Vice President and Chief Compliance Officer
Leslie Magnus

Leslie Magnus

Senior Vice President, Medical Affairs
Show more

Synergy Pharmaceuticals Office Locations

Synergy Pharmaceuticals has an office in New York
New York, US (HQ)
420 Lexington Ave #2012
Show all (1)

Synergy Pharmaceuticals Financials and Metrics

Synergy Pharmaceuticals Revenue

Synergy Pharmaceuticals's revenue was reported to be $16.82 m in FY, 2017
USD

Revenue (Q3, 2018)

11.1m

Gross profit (Q3, 2018)

7.2m

Gross profit margin (Q3, 2018), %

64.7%

Net income (Q3, 2018)

(34.5m)

EBIT (Q3, 2018)

(29.6m)

Market capitalization (7-Mar-2019)

7.4m

Closing stock price (7-Mar-2019)

0.0

Cash (30-Sep-2018)

45.6m
Synergy Pharmaceuticals's current market capitalization is $7.4 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

16.8m

Cost of goods sold

8.8m

Gross profit

8.0m

Gross profit Margin, %

48%
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

98.0k2.3m5.0m8.6m12.3m11.1m

Cost of goods sold

1.8m2.9m2.2m3.7m3.9m3.9m

Gross profit

(1.7m)(576.0k)2.8m4.9m8.4m7.2m

Gross profit Margin, %

(1742%)(25%)57%57%68%65%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

18.1m146.5m61.7m82.4m137.0m

Accounts Receivable

554.0k6.5m

Inventories

3.7m3.8m3.3m5.6m17.2m

Current Assets

71.9m200.2m115.1m88.9m165.2m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

12.1m20.6m1.2m12.8m78.7m61.7m41.9m84.2m141.2m109.1m139.3m82.0m117.8m98.7m61.2m45.6m

Accounts Receivable

6.3m1.8m5.0m7.4m8.5m9.2m

Inventories

9.6m11.9m13.0m16.2m17.6m21.5m

Current Assets

87.3m76.2m56.0m36.9m182.3m164.0m143.1m87.5m145.5m110.8m163.3m104.0m144.4m131.2m95.1m81.7m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(62.1m)(95.7m)(117.5m)(198.6m)(224.3m)

Depreciation and Amortization

56.0k120.0k163.0k233.0k165.0k

Inventories

(2.2m)(124.0k)531.0k(5.6m)(11.6m)

Accounts Payable

7.1m316.0k1.9m11.5m8.7m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(13.5m)(16.2m)(42.1m)(65.2m)(27.4m)(61.1m)(87.1m)(59.9m)(98.5m)(40.2m)(64.6m)(138.5m)(187.4m)(36.1m)(65.8m)(100.3m)

Depreciation and Amortization

28.0k57.0k86.0k67.0k103.0k79.0k41.0k80.0k121.0k48.0k106.0k179.0k

Inventories

(4.0m)(6.2m)(7.4m)1.0m(395.0k)(4.3m)

Accounts Payable

(3.0m)2.4m3.1m11.2m(1.3m)(1.0m)13.6m4.5m15.8m9.5m13.7m2.1m(1.0m)(9.5m)(5.1m)
USDY, 2018

Financial Leverage

-0.9 x
Show all financial metrics

Synergy Pharmaceuticals Operating Metrics

FY, 2016FY, 2017

Patents (US)

21 24

Patents Pending (Foreign)

82 98

Patents Pending (US)

17 19
Show all operating metrics

Synergy Pharmaceuticals Online and Social Media Presence

Embed Graph

Synergy Pharmaceuticals News and Updates

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Synergy Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - SGYP

NEW YORK, April 9, 2019 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed on behalf of investors in Synergy Pharmaceutical, Inc. ("Synergy" or the "Company") (NASDAQ: SGYP) against certain of the Company's current and former officers and directors. The...

Synergy Pharmaceuticals Announces Completion of Sale to Bausch Health

NEW YORK, March 6, 2019 /PRNewswire/ -- Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) (the "Company" or "Synergy"), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today confirmed that the previously announced sale of...

Synergy Pharmaceuticals Receives Court Approval for the Sale of Its Assets to Bausch Health

NEW YORK, March 1, 2019 /PRNewswire/ -- Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) (the "Company" or "Synergy"), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today confirmed that the previously announced agreement...

Synergy Pharmaceuticals Receives Court Approval for the Sale of Its Assets to Bausch Health

NEW YORK, March 1, 2019 /PRNewswire/ -- Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) (the "Company" or "Synergy"), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today confirmed that the previously announced agreement...

Bausch Health to Acquire Certain Assets of Synergy Pharmaceuticals Inc.

Bausch Health and Synergy to Seek Bankruptcy Court Approval of Sale on March 1, 2019 LAVAL, Quebec, Feb. 26, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that the Company was selected as the successful bidder to...

Thinking about buying stock in Lloyds Banking Group, New Age Beverages Co, Synergy Pharmaceuticals, Tilray or Uxin?

NEW YORK, Dec. 13, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LYG, NBEV, SGYP, TLRY, and UXIN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ...
Show more

Synergy Pharmaceuticals Blogs

Synergy Pharmaceuticals Confirms Bausch Health as Successful Bidder for Its Business Assets

NEW YORK, Feb. 26, 2019 /PRNewswire/ -- Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) (the "Company" or "Synergy"), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today confirmed that the previously announced agreement with Baus…

Synergy Pharmaceuticals Reports Third Quarter 2018 Financial Results and Business Update

NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for the three months en…

Synergy Pharmaceuticals Names Dr. Melvin K. Spigelman Chairman

NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that Melvin K. Spigelman, M.D., who has served as an Independen…

Synergy Pharmaceuticals Provides Business Update

NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) (the “Company” or “Synergy”), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today provided a business update. S…

Synergy Pharmaceuticals Presents New Analyses Supporting the Use of TRULANCE® (plecanatide) in Two Patient Populations at the American College of Gastroenterology (ACG) Annual Scientific Meeting

New analyses results reinforce effectiveness and safety for the use of TRULANCE in adults with CIC or IBS-C NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization …

Synergy Pharmaceuticals to Present New Analyses of TRULANCE® (Plecanatide) at the American College of Gastroenterology (ACG) Annual Scientific Meeting

New analyses further reinforce effectiveness and safety in important subpopulations of adults with CIC or IBS-C NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercializat…
Show more

Synergy Pharmaceuticals Frequently Asked Questions

  • When was Synergy Pharmaceuticals founded?

    Synergy Pharmaceuticals was founded in 1992.

  • Who are Synergy Pharmaceuticals key executives?

    Synergy Pharmaceuticals's key executives are Pharm.D Troy Hamilton, Patrick Griffin and Gary G. Gemignani.

  • How many employees does Synergy Pharmaceuticals have?

    Synergy Pharmaceuticals has 116 employees.

  • What is Synergy Pharmaceuticals revenue?

    Latest Synergy Pharmaceuticals annual revenue is $16.8 m.

  • What is Synergy Pharmaceuticals revenue per employee?

    Latest Synergy Pharmaceuticals revenue per employee is $145 k.

  • Who are Synergy Pharmaceuticals competitors?

    Competitors of Synergy Pharmaceuticals include Retrophin, GBT (Global Blood Therapeutics) and Melinta Therapeutics.

  • Where is Synergy Pharmaceuticals headquarters?

    Synergy Pharmaceuticals headquarters is located at 420 Lexington Ave #2012, New York.

  • Where are Synergy Pharmaceuticals offices?

    Synergy Pharmaceuticals has an office in New York.

  • How many offices does Synergy Pharmaceuticals have?

    Synergy Pharmaceuticals has 1 office.